xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.
lamictal tuggu-/dreifitafla 50 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 50 mg
lamictal tuggu-/dreifitafla 5 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 5 mg
lamictal tuggu-/dreifitafla 25 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 25 mg
lamictal tuggu-/dreifitafla 200 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 200 mg
lamictal tuggu-/dreifitafla 2 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 2 mg
lamictal tuggu-/dreifitafla 100 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 100 mg
seroxat filmuhúðuð tafla 20 mg
glaxosmithkline pharma a/s - paroxetinum hýdróklóríð - filmuhúðuð tafla - 20 mg
seroxat filmuhúðuð tafla 10 mg
glaxosmithkline pharma a/s - paroxetinum hýdróklóríð - filmuhúðuð tafla - 10 mg
serevent innúðalyf, dreifa 25 míkróg/skammt
glaxosmithkline pharma a/s - salmeterolum xínafóat - innúðalyf, dreifa - 25 míkróg/skammt